Jazz Pharmaceuticals Q1 2024 Adj EPS $2.68 Misses $4.18 Estimate, Sales $901.983M Miss $953.896M Estimate
Portfolio Pulse from Benzinga Newsdesk
Jazz Pharmaceuticals reported Q1 2024 adjusted EPS of $2.68, missing the $4.18 estimate, and sales of $901.983M, missing the $953.896M estimate. This represents a 1.03% increase in sales compared to the same period last year.
May 01, 2024 | 9:08 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Jazz Pharmaceuticals missed Q1 2024 earnings and sales estimates, with adjusted EPS at $2.68 and sales at $901.983M, indicating a potential negative short-term impact on its stock price.
Missing both earnings and sales estimates typically leads to negative investor sentiment in the short term, potentially causing a decrease in stock price. The reported figures were significantly below analyst expectations, which could lead to a lack of confidence among investors and a possible sell-off.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100